Reviews & perspectives
mAbs
Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry
This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.
DOI: 10.1080/19420862.2026.2699078